Skip to content
thestock.space

Brooks Laboratories (BROOKS) had a P/E of 14.1× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 44% below their 52-week high. Its ROCE of 20% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 11% a year over 3 years, though net profit is above operating profit, which points to a one-off gain. The company has almost no debt. It is a small-cap company with a market cap of ₹186 Cr, ranked 97th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 39% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹65.99
Day high
₹67.90
Day low
₹62.60
Prev. close
₹66.45
Volume
1.6 L

Health check

2 good · 1 fair · 2 to check
  • ReturnsBehind

    −39.4% over a year, better than 0 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthSteady

    Sales +11.0% a year over 3 years.

  • ProfitabilityStrong

    ROCE 20.0% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.07× equity, interest covered 35.2×, Piotroski 6 of 9.

  • Red flags4 to check

    Quarterly profit down 118.6% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹186 Cr, #97 of 154 in its industry by size.

Moves with the market

Beta 1.04 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹83 Cr · profit ₹13 Cr
Market cap
₹186 Cr
Small cap
P/E
14.1
Industry 28.7
Price to book
1.52
Peers 4.99
Dividend yield
0.00%
ROE
22.3%
Peers 14.7%
ROCE
20.0%
Peers 17.9%
Debt to equity
0.07
Debt ₹8.52 Cr
EPS (TTM)
₹4.49
Face value ₹10
OPM (TTM)
7.0%
Net margin 15.9%
Sales growth
−10.0%
Latest quarter vs a year ago
Profit growth
−118.6%
Latest quarter vs a year ago
Price to sales
2.24
EV/EBITDA 31.5

Strengths and risks

Strengths

  • Return on equity of 22.3%.
  • Return on capital employed of 20.0%.
  • Practically debt-free.

Risks to check

  • Quarterly profit down 118.6% on a year ago.
  • Quarterly sales down 10.0% on a year ago.
  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.
  • 44% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Brooks Laboratories

Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products,…

Headquarters
Mumbai
Employees
347
Sector
Healthcare
ISIN
INE650L01011
Website
brookslabs.net

Price range

52 weeks

₹36.30₹112.40

Today

₹62.60₹67.90
Avg volume (3M)
97.2K
1-year return
minus 39.4%
From 52-week high
minus 43.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
BROOKSBrooks Laboratories63.25minus 4.82%18614.11.5220.0%22.3%7.0%11.0%–0.00%minus 39.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
25.523.516.620.223
22.420.915.819.521.1
3.12.50.70.71.9
12.3%10.8%4.4%3.4%8.1%
7.26.15.31.3−3
0.30.30.20.10.2
0.40.40.40.40.4
9.685.51.5−1.8
9.685.51.5−1.8
3.252.711.870.52-0.61

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+11.0%
ROE
22.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
62.57982.285.4
–+26.5%+4.0%+3.9%
8975.874.178.3
−26.53.28.17.1
−42.5%4.1%9.9%8.3%
−3.4−20.3−12.419.4
20.70.80.7
71.81.61.6
0.50−3.10.4
−38.4−19.6−9.824.6
19.1%−0.1%−1.8%–
−20.9−19.6−1024.6
-12.57-7.67-3.728.35

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
24.726.229.529.5
49.339.368.693.2
6.55.67.68.5
29.119.21817
11090.4124148
14.813.614.216.3
––0.31.7
0.20.10.10.2
00.106.6
94.576.6109123
11090.4124148

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−14.5−9.82.69.3
0.50.2−45.1−2.9
11.49.742.40.2
−2.60.1−0.16.5
−0.5−0.4−0.9−3.5
−15−10.21.75.8

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 9.9% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you